NeuroSense Therapeutics Ltd., a foreign private issuer, has submitted a Form 6-K report to the United States Securities and Exchange Commission (SEC) for February 2024. The report includes an updated presentation detailing the company's business and recent clinical outcomes. Notably, the presentation, furnished as Exhibit 99.1, showcases additional positive clinical outcomes related to Quality of Life and complication-free survival, presented on slides 27-31, as well as drug tolerability data on slide 18. NeuroSense emphasizes that the updated information in the presentation should be viewed in conjunction with its SEC filings and other public disclosures. The company has confirmed the report by signature from Alon Ben-Noon, authorized representative, dated February 22, 2024.

NeuroSense Therapeutics Ltd., a foreign private issuer, has submitted a Form 6-K report to the United States Securities and Exchange Commission (SEC) for February 2024. The report includes an updated presentation detailing the company's business and recent clinical outcomes. Notably, the presentation, furnished as Exhibit 99.1, showcases additional positive clinical outcomes related to Quality of Life and complication-free survival, presented on slides 27-31, as well as drug tolerability data on slide 18. NeuroSense emphasizes that the updated information in the presentation should be viewed in conjunction with its SEC filings and other public disclosures. The company has confirmed the report by signature from Alon Ben-Noon, authorized representative, dated February 22, 2024.